Plus therapeutics initiates part b of respect-lm phase 1/2a trial for leptomeningeal metastase

Austin, texas, sept. 05, 2023 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced treatment of the first patient in part b (cohort 4) of the respect-lm phase 1/2a dose escalation clinical trial of rhenium (186re) obisbemeda for the treatment of leptomeningeal metastases (lm) from solid tumors.
pstv Ratings Summary
pstv Quant Ranking